MONTREAL, July 23,
2021 /CNW Telbec/ - Theratechnologies Inc.
("Theratechnologies" or the "Company") (TSX: TH)
(NASDAQ: THTX), a biopharmaceutical company focused on the
development and commercialization of innovative
therapies, today announced that it has established an
at-the-market ("ATM") equity program allowing
Theratechnologies to issue and sell up to US $50 million
common shares from treasury (the "Common Shares") to the
public at the Company's sole discretion and at the prevailing
market price. Sales of the Common Shares under the ATM program will
be made pursuant to the terms of a sales agreement dated
July 23, 2021 with Cantor Fitzgerald
& Co (the "Agent"). The volume and timing of
distributions under the ATM program, if any, will be determined at
the Company's sole discretion, subject to applicable regulatory
limitations.
All Common Shares sold pursuant to the ATM will be sold through
the Nasdaq Capital Market or another marketplace upon which the
Common Shares are listed, quoted or otherwise traded in
the United States, at the
prevailing market price at the time of sale.
In connection with the ATM, Theratechnologies has filed a
prospectus supplement dated July 23,
2021 (the "Prospectus Supplement") with the
securities regulatory authorities in each of the provinces of
Canada and with the United States Securities and Exchange
Commission ("SEC"), which supplements the Company's Canadian
short form base shelf prospectus dated November 15, 2019 (the "Base Shelf
Prospectus"), and the Company's shelf registration statement on
Form F-10 declared effective on November 15, 2019 by the SEC. A copy of the
Prospectus Supplement is available on our SEDAR profile at
www.sedar.com or on EDGAR at www.sec.gov. Alternatively, a copy of
the Prospectus Supplement and accompanying base shelf prospectus
are available upon request by contacting the Agent, Attn: Capital
Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by email at
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any offer,
solicitation or sale of, the securities under the ATM program in
any province, state or jurisdiction in which such offer,
solicitation or sale would be unlawful.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies addressing unmet medical
needs. Further information about Theratechnologies is available on
the Company's website at www.theratech.com, on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov.
Forward-Looking Information
This press release contains forward-looking statements, within
the meaning of Section 21E of the Securities Exchange Act
of 1934, as amended and forward-looking information under
applicable Canadian securities laws (such forward-looking
statements and forward-looking information are collectively
referred to herein as "forward-looking statements"), that
are based on our management's beliefs and assumptions and on
information currently available to our management. You can identify
forward-looking statements by terms such as "may", "will",
"should", "could", "would", "outlook", "believe", "plan",
"envisage", "anticipate", "expect" and "estimate", or the negatives
of these terms, or variations of them. The forward-looking
statements contained in this press release include, but are not
limited to, statements regarding the offer and sale of Common
Shares, and the use of proceeds from the ATM program.
Forward-looking statements are based upon a number of
assumptions and include, but are not limited to, the following: the
Covid-19 pandemic will have limited adverse effect on the ATM
program, the price, volume, timing and the regulatory approval for
any distributions, the proceeds from the ATM program will be
allocated for the activities set forth herein and we will have
enough funds to carry out our business plan.
We refer potential investors to the "Risk Factors" section of
our annual information form dated February
24, 2021 available on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov as an exhibit to our report on Form 40-F dated
February 24, 2021 under
Theratechnologies' public filings for additional risks regarding
the conduct of our business and Theratechnologies. The reader is
cautioned to consider these and other risks and uncertainties
carefully and not to put undue reliance on forward-looking
statements. Forward-looking statements reflect current expectations
regarding future events and speak only as of the date of this press
release and represent our expectations as of that date.
We undertake no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise, except as
may be required by applicable law.
SOURCE Theratechnologies Inc.
